Short-chain fructooligosaccharides protect against intestinal injury in NEC by restoring AKT/GSK-3β signaling

Key Points

• Intestinal injury is reduced by short-chain fructooligosaccharides, highlighting their protective potential.
• Key evidence shows that treatment with fructooligosaccharides restores AKT/GSK-3β signaling in neonatal models.
• Analysis of signaling pathways activation demonstrates the role of fructooligosaccharides in protecting gut health.
• Results indicate significant implications for NEC management in neonatal intensive care settings.